Page last updated: 2024-10-30

labetalol and Arterial Obstructive Diseases

labetalol has been researched along with Arterial Obstructive Diseases in 1 studies

Labetalol: A salicylamide derivative that is a non-cardioselective blocker of BETA-ADRENERGIC RECEPTORS and ALPHA-1 ADRENERGIC RECEPTORS.
labetalol : A diastereoisomeric mixture of approximately equal amounts of all four possible stereoisomers ((R,S)-labetolol, (S,R)-labetolol, (S,S)-labetalol and (R,R)-labetalol). It is an adrenergic antagonist used to treat high blood pressure.
2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide : A member of the class of benzamides that is benzamide substituted by a hydroxy group at position 2 and by a 1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl group at position 5.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19901 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Chiariello, M1
Brevetti, G1
DeRosa, G1
Acunzo, R1
Petillo, F1
Rengo, F1
Condorelli, M1

Other Studies

1 other study available for labetalol and Arterial Obstructive Diseases

ArticleYear
Protective effects of simultaneous alpha and beta adrenergic receptor blockade on myocardial cell necrosis after coronary arterial occlusion in rats.
    The American journal of cardiology, 1980, Volume: 46, Issue:2

    Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Arterial Occlusive Diseases; Cor

1980